Denmark's 'Novo Town' holds its breath as Wegovy fever fades
In Denmark's seaside town of Kalundborg, also known as "Novo Town", therapist Heidi Thron Rune has learnt to live with the noise of building work as new facilities take shape to meet demand for Nov...
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why
In the most recent trading session, Novo Nordisk (NVO) closed at $60.71, indicating a -1.12% shift from the previous trading day.
DEADLINE APPROACHING: Berger Montague Advises Nordisk A/S (NYSE: NVO) Investors to Inquire About a Securities Fraud Class Action by September 30, 2025
PHILADELPHIA , Sept. 22, 2025 /PRNewswire/ -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Novo Nordisk A/S.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
NVO IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors with Losses in Excess of $100K to Secure Counsel Bef...
NEW YORK, Sept. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28...
Novo Nordisk: Attractive Buying Opportunity In A Distracted Market
Novo Nordisk's recent stock decline looks like a market overreaction to a lot of noise, presenting a strong long-term buying opportunity at a discounted price. The new CEO's restructuring could imp...
Novo Nordisk's Wegovy Pill Shows Similar Weight-Loss to Its Shot, Study Finds
Production is under way and the pill, which helped patients lose an average 16.6% of their weight, is pending regulatory approval in the U.S.
Wegovy pill offers 'significant' weight reduction, Novo Nordisk says, as oral obesity drug race intensifies
Trial results showed the "Wegovy pill" led to average weight reduction of 16.6% after 64 weeks, Novo Nordisk said. The company's Chief Science Officer Martin Holst Lange told CNBC that oral treatme...
Novo Nordisk A/S - Special Call
Novo Nordisk A/S - Special Call Company Participants Martin Lange - EVP of R&D, CSO and Member of the Management Board Conference Call Participants Martin Parkhoi - SEB, Research Division Michael N...
Novo Nordisk's oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Bagsværd, Denmark, Plainsboro, NJ, 17 September 2025 – Today, The New England Journal of Medicine published the results from the OASIS 4 phase 3 trial that studied the efficacy and safety of the in...
Novo Nordisk finds its footing again
After a bruising year, Novo Nordisk (NYSE:NVO) is back in favour. Berenberg has upgraded the Danish drugmaker to 'buy', setting a target price of DKK425 against a current DKK359.
Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors – Contact Levi & Korsinsky
NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Novo Nordisk A/S Investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2025 Deadline to file Lead Plaintiff Motion
Investors can contact the law firm at no cost to learn more about recovering their losses
Novo Nordisk's Wegovy Helps Suppress Thoughts About Food, Study Suggests
The number of people who reported experiencing constant thoughts about food declined by 46% after starting treatment with Wegovy, the pharma giant said.
Novo Nordisk: The Market Is Giving Us A Free Lunch
Novo Nordisk A/S's stock is severely oversold as the market overreacts to short-term news, which has created what appears to be a rare buying opportunity. While Q2 guidance was lowered, the underly...
Related Companies